Adicet Bio Inc (ACET)
1.83
-0.04
(-2.40%)
USD |
NASDAQ |
Apr 25, 11:58
Adicet Bio Cash from Operations (Quarterly): -23.49M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -23.49M |
| September 30, 2023 | -21.24M |
| June 30, 2023 | -24.90M |
| March 31, 2023 | -24.09M |
| December 31, 2022 | -18.84M |
| September 30, 2022 | -15.33M |
| June 30, 2022 | -14.70M |
| March 31, 2022 | 4.105M |
| Date | Value |
|---|---|
| December 31, 2021 | -13.44M |
| September 30, 2021 | -9.684M |
| June 30, 2021 | -12.78M |
| March 31, 2021 | -15.15M |
| December 31, 2020 | -13.34M |
| September 30, 2020 | -7.849M |
| June 30, 2020 | -12.01M |
| March 31, 2020 | -8.352M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-24.90M
Minimum
Jun 2023
4.105M
Maximum
Mar 2022
-14.44M
Average
-14.07M
Median
Cash from Operations (Quarterly) Benchmarks
| Sagimet Biosciences Inc | -7.083M |
| Catalyst Pharmaceuticals Inc | 55.65M |
| Codexis Inc | -11.04M |
| Annexon Inc | -23.48M |
| Inhibrx Inc | -56.82M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.136M |
| Cash from Financing (Quarterly) | 0.076M |
| Free Cash Flow | -98.18M |
| Free Cash Flow Per Share (Quarterly) | -0.5473 |
| Free Cash Flow Yield | -124.7% |